BID Protein

Produktnummer ABIN7319367

Produktdetails

Target: BID (BH3 Interacting Domain Death Agonist (BID))

Protein-Typ: Recombinant

Spezies: Human

Quelle: Escherichia coli (E. coli)

Verwendungszweck: Recombinant Human BID Protein

Sequenz: Met 1-Asp195

Produktmerkmale: Recombinant Human BH3-Interacting Domain Death Agonist is produced by our E.coli expression system and the target gene encoding Met1-Asp195 is expressed.

Reinheit: > 95 % as determined by reducing SDS-PAGE.

Endotoxin-Niveau: < 1.0 EU per μg as determined by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Frozen, Liquid

Buffer: Supplied as a 0.2 μm filtered solution of 20 mM PB, 100 mM KCl, pH 7.4.

Lagerung: -20 °C

Informationen zur Lagerung: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Antigendetails

Target: BID (BH3 Interacting Domain Death Agonist (BID))

Andere Bezeichnung: BID (BID Produkte)

Synonyme: FP497 Protein, 2700049M22Rik Protein, AI875481 Protein, AU022477 Protein, BID Protein, bid Protein, si:ch211-238n5.6 Protein, fp497 Protein, xbid Protein, DKFZp469E066 Protein, BH3 interacting domain death agonist Protein, BH3 interacting domain death agonist S homeolog Protein, BID Protein, Bid Protein, bida Protein, bid.S Protein, bid Protein

Hintergrund:

Background: BH3-Interacting Domain Death Agonist (BID) is a member of the Bcl-2 protein family which regulates outer mitochondrial membrane permeability. BID is a pro-apoptotic member that causes cytochrome c to be released from the mitochondria intermembrane space into the cytosol. Interaction of Bid with Bak causes altered mitochondrial membrane permeability. BID contains only the BH3 domain, which is required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. It is an integrating key regulator of the intrinsic death pathway that amplifies caspase-dependent and caspase-independent execution of neuronal apoptosis. Therefore pharmacological inhibition of BID provides a promising therapeutic strategy in neurological diseases where programmed cell death is prominent, and also offer a new strategy for the treatment of acute renal failure associated with ischemia-reperfusion. BID receives direct inputs from a key regulator of the cell cycle arrest/DNA repair machinery (ATM), and therefore is an excellent candidate to coordinate genotoxic stress responses and apoptotic cell death. BID is a novel pro-apoptosis Bcl-2 family protein that is activated by caspase 8 in response to Fas/TNF-R1 death receptor signals. Deletion of BID inhibits carcinogenesis in the liver, although this genetic alteration promotes tumorigenesis in the myeloid cells. This is likely related to the function of BID to promote cell cycle progression into S phase. BID could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint.

Synonym: BH3-Interacting Domain Death Agonist, p22 BID, BID

Molekulargewicht: 22.0 kDa

Pathways: Apoptose, Caspase Kaskade in der Apoptose, Positive Regulation of Endopeptidase Activity